Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 3
2005 1
2006 3
2007 5
2008 11
2009 9
2010 4
2011 14
2012 20
2013 22
2014 26
2015 29
2016 29
2017 25
2018 36
2019 27
2020 34
2021 43
2022 34
2023 41
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Results by year

Filters applied: . Clear all
Page 1
Introduction.
Kanetsuna Y, Maruyama S. Kanetsuna Y, et al. Among authors: maruyama s. Nephron. 2023;147 Suppl 1:5. doi: 10.1159/000533694. Epub 2023 Aug 23. Nephron. 2023. PMID: 37611555 Free article. No abstract available.
Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Hayashi T, et al. Among authors: maruyama s. Clin J Am Soc Nephrol. 2020 May 7;15(5):608-615. doi: 10.2215/CJN.08900719. Epub 2020 Apr 3. Clin J Am Soc Nephrol. 2020. PMID: 32245781 Free PMC article. Clinical Trial.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators. Kimura K, et al. Among authors: maruyama s. Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1. Am J Kidney Dis. 2018. PMID: 30177485 Free article. Clinical Trial.
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Tani Y, Wada J, Sugiyama H, Tsuruya K, Nakano T, Maruyama S, Wada T, Yamagata K, Narita I, Tamura K, Yanagita M, Terada Y, Shigematsu T, Sofue T, Ito T, Okada H, Nakashima N, Kataoka H, Ohe K, Okada M, Itano S, Nishiyama A, Kanda E, Ueki K, Kashihara N. Nagasu H, et al. Among authors: maruyama s. Diabetes Care. 2021 Nov;44(11):2542-2551. doi: 10.2337/dc21-1081. Epub 2021 Sep 30. Diabetes Care. 2021. PMID: 34593566 Free PMC article.
microRNA-induced IgA nephropathy.
Imai E, Maruyama S. Imai E, et al. Among authors: maruyama s. J Am Soc Nephrol. 2012 May;23(5):765-6. doi: 10.1681/ASN.2012030249. Epub 2012 Apr 12. J Am Soc Nephrol. 2012. PMID: 22499587 No abstract available.
Immunology of membranous nephropathy.
Akiyama S, Imai E, Maruyama S. Akiyama S, et al. Among authors: maruyama s. F1000Res. 2019 May 24;8:F1000 Faculty Rev-734. doi: 10.12688/f1000research.17589.1. eCollection 2019. F1000Res. 2019. PMID: 31168358 Free PMC article. Review.
Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Kataoka H, Ohe K, Okada M, Kashihara N. Sofue T, et al. Among authors: maruyama s. PLoS One. 2020 Jul 20;15(7):e0236132. doi: 10.1371/journal.pone.0236132. eCollection 2020. PLoS One. 2020. PMID: 32687544 Free PMC article.
Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease.
Hasegawa T, Imaizumi T, Hamano T, Murotani K, Fujii N, Komaba H, Ando M, Maruyama S, Nangaku M, Nitta K, Hirakata H, Isaka Y, Wada T, Fukagawa M. Hasegawa T, et al. Among authors: maruyama s. Nephrol Dial Transplant. 2023 Nov 30;38(12):2713-2722. doi: 10.1093/ndt/gfad096. Nephrol Dial Transplant. 2023. PMID: 37202214 Free PMC article.
Excess risk of cardiovascular events in patients in the United States vs. Japan with chronic kidney disease is mediated mainly by left ventricular structure and function.
Imaizumi T, Fujii N, Hamano T, Yang W, Taguri M, Kansal M, Mehta R, Shafi T, Taliercio J, Go A, Rao P, Hamm LL, Deo R, Maruyama S, Fukagawa M, Feldman HI; CRIC Study Investigators. Imaizumi T, et al. Among authors: maruyama s. Kidney Int. 2023 May;103(5):949-961. doi: 10.1016/j.kint.2023.01.008. Epub 2023 Feb 2. Kidney Int. 2023. PMID: 36738890 Free PMC article.
Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan.
Nishimura JI, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, Fukamizu Y, Akiyama H, Hayashi H, Nakano T, Maruyama S. Nishimura JI, et al. Among authors: maruyama s. Int J Hematol. 2023 Oct;118(4):419-431. doi: 10.1007/s12185-023-03630-x. Epub 2023 Jul 29. Int J Hematol. 2023. PMID: 37515657
363 results